Poolbeg Pharma plc (LON:POLB) investor presentation with CEO Jeremy Skillington. Insights on company overview, key programs, progress in 2023, and market opportunities...
Poolbeg Pharma plc (LON: POLB, OTCQB: POLBF) announces the posting of its Annual Report and Accounts, with details of the upcoming Annual General Meeting on June 13, 2024...
Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF) receives fully granted US patent for Immunomodulator II, enhancing value and attractiveness to potential Pharma partners...
Poolbeg Pharma plc has entered into an exclusive agreement with Silk Road Therapeutics for a novel treatment targeting oral ulcers in Behçet's Disease patients...
Poolbeg Pharma plc announces audited results for 2023, highlighting financial, corporate, and operational achievements. CEO Jeremy Skillington emphasizes potential for significant value creation...
Poolbeg Pharma plc has received a Notice of Allowance from the US Patent Office for its Immunomodulator II patent application, enhancing the value of its promising POLB 001 therapy for potential partners. CEO Jeremy Skillington highlights the potential of POLB 001 in breakthrough cancer immunotherapies...
Poolbeg Pharma (LON:POLB, OTCQB: POLBF) announces a change in Board role and the approval of an Employee Performance Incentive Plan to align objectives and encourage retention. Cathal Friel becomes Executive Chairman, bringing valuable experience from his successful track record in public companies. The plan aims to reward and retain key senior management for sustainable growth...
Poolbeg Pharma plc, a biopharmaceutical company, announces a >$10 billion market opportunity for its cancer immunotherapy-induced CRS therapy, POLB 001. The company aims to address rare and orphan diseases and capitalize on the growing cancer immunotherapy market. With promising results in addressing CRS, Poolbeg is well-positioned to generate revenue and create value for shareholders...
Learn about Poolbeg Pharma Plc's strategic shift towards sustainable revenue and profitability in this Investor Presentation by CEO Jeremy Skillington. Discover their focus on developing innovative medicines for unmet medical needs and their strong financial position. Find out more...
Poolbeg Pharma plc (LON:POLB) investor presentation with CEO Jeremy Skillington. Insights on company overview, key programs, progress in 2023, and market opportunities...
Poolbeg Pharma plc (LON: POLB, OTCQB: POLBF) announces the posting of its Annual Report and Accounts, with details of the upcoming Annual General Meeting on June 13, 2024...
Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF) receives fully granted US patent for Immunomodulator II, enhancing value and attractiveness to potential Pharma partners...
Poolbeg Pharma plc has entered into an exclusive agreement with Silk Road Therapeutics for a novel treatment targeting oral ulcers in Behçet's Disease patients...
Poolbeg Pharma plc announces audited results for 2023, highlighting financial, corporate, and operational achievements. CEO Jeremy Skillington emphasizes potential for significant value creation...
Poolbeg Pharma plc has received a Notice of Allowance from the US Patent Office for its Immunomodulator II patent application, enhancing the value of its promising POLB 001 therapy for potential partners. CEO Jeremy Skillington highlights the potential of POLB 001 in breakthrough cancer immunotherapies...
Poolbeg Pharma (LON:POLB, OTCQB: POLBF) announces a change in Board role and the approval of an Employee Performance Incentive Plan to align objectives and encourage retention. Cathal Friel becomes Executive Chairman, bringing valuable experience from his successful track record in public companies. The plan aims to reward and retain key senior management for sustainable growth...
Poolbeg Pharma plc, a biopharmaceutical company, announces a >$10 billion market opportunity for its cancer immunotherapy-induced CRS therapy, POLB 001. The company aims to address rare and orphan diseases and capitalize on the growing cancer immunotherapy market. With promising results in addressing CRS, Poolbeg is well-positioned to generate revenue and create value for shareholders...
Learn about Poolbeg Pharma Plc's strategic shift towards sustainable revenue and profitability in this Investor Presentation by CEO Jeremy Skillington. Discover their focus on developing innovative medicines for unmet medical needs and their strong financial position. Find out more...
